Case Report
Medullary thyroid carcinoma relapse reversed with dichloroacetate: A case report
- Authors:
-
-
Pages:
889-891
|
Published online on:
September 1, 2010
https://doi.org/10.3892/ol_00000158
- Expand metrics +
Metrics:
Total
Views: 0
(Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0
(Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
A 51-year-old male patient diagnosed with medullary thyroid carcinoma (MTC) in 2001, with progression to lung metastases following adriamycin therapy, was then successfully treated with dimethyltriazenoimidazole carboximide. He remained in partial remission for 7 years following numerous chemotherapy attempts to induce partial remission. In October 2008, the patient, then 58 years old, relapsed with numerous tumors throughout his central body. On December 1, 2008, the tumor marker for MTC, calcitonin, was at 38,611 pg/ml, i.e., much higher than the norm of <20 pg/ml. Since all other chemotherapy attempts had failed, he was ineligible for any new studies. Subsequently, the patient was immediately started on 10 mg/kg of dichloroacetate (DCA). By April 2009, the calcitonin level was reduced to 2,000 pg/ml. In May 2009, a new positron emission tomography showed a dramatic reduction in all tumor locations. The patient presently remains in remission and continues receiving the same dosage of DCA, with his tumor marker remaining stable in laboratory data since November 2009.
View References
|
1
|
Santarpia L, Ye L and Gagel RF: Beyond
RET: potential therapeutic approaches for advanced and metastatic
medullary thyroid carcinoma. J Intern Med. 266:99–113. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cuccuru G: Cellular effects and antitumor
activity of RET inhibitor RPI-1 on MEN2A-associated medullary
thyroid carcinoma. J Natl Cancer Inst. 96:1006–1014. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cakir M and Grossman A: Medullary thyroid
cancer: molecular biology and novel molecular therapies.
Neuroendocrinology. 90:323–348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higgins MJ, Forastiere A and Marur S: New
directions in the systemic treatment of metastatic thyroid cancer.
Oncology. 23:768–775. 2009.PubMed/NCBI
|
|
5
|
Sugawara M, Geffner DL, Martinez D and
Hershman JM: Novel treatment of medullary thyroid cancer. Curr Opin
Endocrinol Diabetes Obes. 16:367–372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fassnacht M, Kreissl MC, Weissmann D and
Allolio B: New targets and therapeutic approaches for endocrine
malignancies. Pharmacol Ther. 123:117–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spruijt L, Naviaux R, McGowan KA, et al:
Nerve conduction changes in patients with mitochondrial diseases
treated with dichloroacetate. Muscle Nerve. 24:916–924. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
American Thyroid Association Guidelines
Task Force. Medullary thyroid cancer: Management Guidelines of the
American Thyroid Association. Thyroid. 19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheung K: Calcitonin measurement in the
evaluation of thyroid nodules in the United States: a
cost-effectiveness and decision analysis. Clin Endocrinol Metab.
93:2173–2180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stacpoole PW, Lorenz A, Thomas R and
Harman E: Dichloroacetate in the treatment of lactic acidosis. Ann
Intern Med. 108:58–63. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Warburg O, Wind F and Negelein E: Uber den
stoffwechsel von Tumoren im Korper. Klin Woch. 5:829–832. 1926.
View Article : Google Scholar
|
|
12
|
Stacpoole PW, Henderson GN, Yan Z and
James MO: Clinical pharmacology and toxicology of dichloroacetate.
Environ Health Perspect. 106:989–994. 1998. View Article : Google Scholar
|
|
13
|
Bonnet S, Archer SL, Allalunis-Turner J,
et al: A mitochondria-K+ channel axis is suppressed in
cancer and its normalization promotes apoptosis and inhibits cancer
growth. Cancer Cell. 11:37–57. 2007.PubMed/NCBI
|
